CTRI/2010/091/000097招募中1 期
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Therapeutic Activity of ORE1001 in Subjects with Ulcerative Colitis
ORE Pharmaceuticals Ltd.0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •INCLUSION CRITERIA
- •1. Does the subject have a documented diagnosis of Ulcerative Colitis as demonstrated clinically and histologically?
- •2.Is the Modified Baron Score greater than or equal to 2 at baseline?
- •3.Is the Truelove-Witts (modified) Score equal or less than 14?
- •4.Does the subject have a minimum of 6 months duration of the disease?
- •5.Does the subject have a stable clinical disease condition either without prescription therapy or with 5-Amino Salicylic Acid (5-ASA) treatment?
- •6.If on 5 ASA-treatment, is the subject on a stable dose for at least 2 weeks prior to this visit and willing to continue on the same regimen until the study is completed?
- •7.Does the subject have normally functioning major organ systems (aside from Gastro-intestinal Tract) as indicated by past medical history, vital signs, physical examination and clinical laboratory results including hematology, coagulation, clinical chemistry and urinalysis?
- •8. Is the subject aged between 18-70 years?
- •9.Has the subject provided voluntary written informed consent to participate in this study?
- •10.If female of child-bearing potential, not pregnant, not nursing, not planning a pregnancy for the duration of the study and has a negative pregnancy test prior to enrollment?
- •11.a) Does the subject agree to use a method of birth control from screening until 30 days post final dose of study drug?
- •b) Do female partners of male subjects enrolled into the study also agree to use an acceptable method of birth control?
- •c) Do the male subjects agree to not donate sperm during the entire course of the study and for 90 days after the last dose of study drug?
排除标准
- •1.Does a clinically significant medical history, medical finding or an ongoing medical or psychiatric condition exist which in the opinion of the Investigator could jeopardize the safety of the subject, impact validity of the study results or interfere with the completion of treatment according to the protocol?
- •2. Does the subject meet exclusion criteria for Alanine Aminotransferase (ALT) or have a serum creatinine greater than 1.5 times the upper limit of normal?
- •3. Is the subject in the opinion of the investigator febrile?
- •4. Has the subject administered the following treatments for Inflammatory Bowel Disease?
- •a)steroids or any topical treatments (enemas) within the last 4 weeks prior to baseline
- •b)immmunosuppressants, immunomodulators or antimetabolites within the 6 weeks prior to this visit
- •c)antibiotic use within 7 days of this visit
- •d)chronic use of any anti-inflammatory drugs (except aminosalicylates) within 7 days of this visit
- •5. Does the subject have a history of illicit drug abuse or positive urine screen for drugs of abuse or history of alcohol abuse acknowledged during the screening interview and/or noted in the subjects medical history at screening?
- •6. Has the subject tested positive during a blood screen for Human Immuno- Deficiency Virus (HIV), Hepatitis B surface antigen (HBsAg) or Hepatitis C infection?
- •7. Does the subject have evidence of infectious colitis, e.g., Clostridium difficile, Amoebiasis, Giardia lamblia, in the stool examination?
- •8. Does the subject have evidence of gastrointestinal parasites as per stool, ova and parasites testing at screening?
- •9. Does the subject have evidence of tuberculosis by whole-blood interferon-release assay?
- •10. Does the subject have any uncontrolled intercurrent illness (e.g., active infection)?
- •11. Does the subject have a history of gastrointestinal cancer?
- •12. Has the subject undergone abdominal surgery or any major surgery in the 28 days prior to this visit?
研究者
相似试验
进行中（未招募）
Unknown
actoSpore® as an adjuvant in the treatment of Bacterial VaginosisCTRI/2023/05/052560Sami Sabinsa Group Limited
进行中（未招募）
1 期
Efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride combination on moderate to severe acute pain in patients with acute low back paiow back painMedDRA version: 21.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 100000004859EUCTR2019-003656-37-HRMenarini International Operations Luxembourg SA510
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability of 14-days treatment with an inhaled dose of QMF149 (500/800) in mild to moderate asthmatic patients.asthmaEUCTR2007-004608-11-FRovartis Pharma Services AG28
已完成
不适用
Boswellia serrata extract 200 mg capsules in subject with Irritable Bowel Syndrome.CTRI/2019/11/022190Inventia Healthcare Limited50
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effects of a 4-week treatment of 30 mg b.i.d BIBW 2948 BS (inhalation powder, hard capsule for HandiHaler®) on epithelial mucin stores and the safety and efficacy in COPD patients with symptoms associated with chronic bronchitis - Effects of BIBW 2948 on epithelial muciEUCTR2006-001975-40-IEBoehringer Ingelheim Limited60